CTMX
CytomX Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.71
+0.82%0
Insider buys (3m)
1
Insider sells (3m)
-$5.0K
Net value (3m)
+20.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 5, 2026 | Carvajal Alejandra · officer: Chief Legal Officer | A-Award | 100,000 | $0.00 |
| Aug 5, 2026 | Carvajal Alejandra · officer: Chief Legal Officer | A-Award | 450,000 | $3.17 |
| Jul 30, 2026 | Fuchs Charles S. · director | A-Award | 118,000 | $3.24 |
| Jun 22, 2026 | Young Matthew P. · director | A-Award | 59,000 | $2.96 |
| Jun 22, 2026 | Jones Elaine V · director | A-Award | 59,000 | $2.96 |
| Jun 22, 2026 | Meyers James R · director | A-Award | 59,000 | $2.96 |
| Jun 22, 2026 | Gilbert Halley E · director | A-Award | 59,000 | $2.96 |
| Jun 22, 2026 | Su Zhen · director | A-Award | 59,000 | $2.96 |
| Jun 22, 2026 | Ashworth Alan · director | A-Award | 59,000 | $2.96 |
| Jun 22, 2026 | Mohindru Mani · director | A-Award | 59,000 | $2.96 |
| Jun 17, 2026 | Ogden Christopher · officer: Chief Financial Officer | Sale | 1,624 | $3.05 |
| Mar 19, 2026 | McCarthy Sean A. · director, officer: CEO | Sale | 118,969 | $6.42 |
| Mar 19, 2026 | BELVIN MARCIA · officer: SVP, Chief Scientific Officer | Sale | 31,492 | $6.42 |
| Mar 19, 2026 | Chu Yu-Waye · officer: Chief Medical Officer | Sale | 21,279 | $6.42 |
| Mar 19, 2026 | Ogden Christopher · officer: Chief Financial Officer | Sale | 19,323 | $6.42 |
| Feb 4, 2026 | Ogden Christopher · officer: Chief Financial Officer | A-Award | 325,000 | $6.09 |
| Feb 4, 2026 | Lester Rachael · officer: Chief Business Officer | A-Award | 50,000 | $6.09 |
| Feb 4, 2026 | BELVIN MARCIA · officer: SVP, Chief Scientific Officer | A-Award | 60,000 | $0.00 |
| Feb 4, 2026 | Lester Rachael · officer: Chief Business Officer | A-Award | 20,000 | $0.00 |
| Feb 4, 2026 | McCarthy Sean A. · director, officer: CEO | A-Award | 980,000 | $6.09 |
| Feb 4, 2026 | Chu Yu-Waye · officer: Chief Medical Officer | A-Award | 300,000 | $6.09 |
| Feb 4, 2026 | McCarthy Sean A. · director, officer: CEO | A-Award | 210,000 | $0.00 |
| Feb 4, 2026 | Chu Yu-Waye · officer: Chief Medical Officer | A-Award | 75,000 | $0.00 |
| Feb 4, 2026 | BELVIN MARCIA · officer: SVP, Chief Scientific Officer | A-Award | 250,000 | $6.09 |
| Feb 4, 2026 | Ogden Christopher · officer: Chief Financial Officer | A-Award | 90,000 | $0.00 |
| Nov 10, 2025 | McCarthy Sean A. · director, officer: CEO | Sale | 101,793 | $4.54 |
| Oct 29, 2025 | Lester Rachael · officer: Chief Business Officer | A-Award | 650,000 | $3.74 |
| Sep 30, 2025 | Chu Yu-Waye · officer: Chief Medical Officer | A-Award | 87,500 | $2.90 |
| Sep 30, 2025 | McCarthy Sean A. · director, officer: CEO | A-Award | 285,000 | $0.00 |
| Sep 30, 2025 | Chu Yu-Waye · officer: Chief Medical Officer | A-Award | 43,750 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 80Increased 60Reduced 29Sold out 179
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 31,955,637 | May 15, 2026 |
| KYNAM CAPITAL MANAGEMENT, LP | Increased | 15,013,093 | May 15, 2026 |
| BANK OF AMERICA CORP /DE/ | Increased | 10,202,785 | May 18, 2026 |
| PERCEPTIVE ADVISORS LLC | Increased | 10,098,824 | May 29, 2026 |
| VR ADVISER, LLC | Reduced | 9,982,124 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 8,733,118 | May 15, 2026 |
| POINT72 ASSET MANAGEMENT, L.P. | Increased | 7,875,390 | May 15, 2026 |
| CITADEL ADVISORS LLC | Increased | 5,899,193 | May 15, 2026 |
| STATE STREET CORP | Increased | 5,663,408 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 5,228,280 | May 13, 2026 |
| BAKER BROS. ADVISORS LP | Increased | 4,975,826 | May 15, 2026 |
| Elmind Capital, LP | Increased | 4,550,000 | May 15, 2026 |
| NEXTECH INVEST, LTD. | New Position | 4,449,932 | May 15, 2026 |
| MARSHALL WACE, LLP | Increased | 4,138,176 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 3,660,190 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 5, 2026